Your browser doesn't support javascript.
loading
Development of a Robust Manufacturing Route for Molnupiravir, an Antiviral for the Treatment of COVID-19.
Fier, Patrick S; Xu, Yingju; Poirier, Marc; Brito, Gilmar; Zheng, Michelle; Bade, Rachel; Sirota, Eric; Stone, Kevin; Tan, Lushi; Humphrey, Guy R; Chang, Darryl; Bothe, Jameson; Zhang, Yongqian; Bernardoni, Frank; Castro, Steve; Zompa, Michael A; Taylor, Jerry; Sirk, Kevin M; Diaz-Santana, Anthony; Diribe, Ike; Emerson, Khateeta M; Krishnamurthi, Bharath; Zhao, Ralph; Ward, Michael; Xiao, Chengqian; Ouyand, Honggui; Zhan, Jianfeng; Morris, William J.
Afiliación
  • Fier PS; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Xu Y; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Poirier M; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Brito G; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Zheng M; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Bade R; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Sirota E; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Stone K; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Tan L; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Humphrey GR; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Chang D; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Bothe J; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Zhang Y; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Bernardoni F; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Castro S; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Zompa MA; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Taylor J; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Sirk KM; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Diaz-Santana A; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Diribe I; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Emerson KM; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Krishnamurthi B; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Zhao R; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Ward M; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Xiao C; WuXi AppTec Co., Ltd., WaiGaoQiao Free Trade Zone, Shanghai 200131, China.
  • Ouyand H; WuXi AppTec Co., Ltd., WaiGaoQiao Free Trade Zone, Shanghai 200131, China.
  • Zhan J; WuXi AppTec Co., Ltd., WaiGaoQiao Free Trade Zone, Shanghai 200131, China.
  • Morris WJ; Department of Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Org Process Res Dev ; 25(12): 2806-2815, 2021 Dec 17.
Article en En | MEDLINE | ID: mdl-35095257
ABSTRACT
Herein is described the development of a large-scale manufacturing process for molnupiravir, an orally dosed antiviral that was recently demonstrated to be efficacious for the treatment of patients with COVID-19. The yield, robustness, and efficiency of each of the five steps were improved, ultimately culminating in a 1.6-fold improvement in overall yield and a dramatic increase in the overall throughput compared to the baseline process.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2021 Tipo del documento: Article